Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06183931 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT06183931 · ClinicalTrials.gov record · last posted 2026-08-10

Study of ALXN2220 Versus Placebo in Adults With ATTR-CM

Name: Study of ALXN2220 Versus Placebo in Adults With ATTR-CM — clinical trial record (NCT06183931)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: DepleTTR-CM

StatusActive, Not Recruiting

PhasePhase 3

SponsorAlexion Pharmaceuticals, Inc.

Started2024-01-11

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

The primary objective of this study is to access the efficacy of ALXN2220 in the treatment of adult participants with ATTR-CM by evaluating the difference between the ALXN2220 and placebo groups as assessed by the total occurrences of all-cause mortality (ACM) and cardiovascular (CV) clinical events.

Protocol amendment history 2 changes detected by DataLookout

2026-08-11

Primary completion pushed: 2027-06-07 → 2027-12-06

2026-08-11

Completion pushed: 2027-10-05 → 2028-04-05

Trial Details

NCT Number	NCT06183931
Lead Sponsor	Alexion Pharmaceuticals, Inc.
Conditions	Transthyretin Amyloid Cardiomyopathy
Enrollment	1,181 participants
Start Date	2024-01-11
Primary Completion	2027-12-06 (estimated)
Study Completion	2028-04-05 (estimated)
Updated on ClinicalTrials.gov	2026-08-10